Effects of naproxen on immune responses in a colchicine-induced rat model of Alzheimer's disease

NeuroImmunoModulation

Volumn 21, Issue 6, 2014, Pages 304-321

  Sil, Susmita ^a   Goswami, Ananda Raj ^a   Dutta, Goutam ^a   Ghosh, Tusharkanti ^a  

^a UNIVERSITY OF CALCUTTA   (India)

Author keywords

Alzheimer's disease; Immune responses; Naproxen; Neurodegeneration

Indexed keywords

COLCHICINE; NAPROXEN; NITRITE; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; HYDROCORTISONE; CYTOKINE; NONSTEROID ANTIINFLAMMATORY AGENT; TUBULIN MODULATOR;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHROMATOLYSIS; CHRONOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DEGENERATIVE DISEASE; DOSE RESPONSE; HIPPOCAMPUS; IMMUNE RESPONSE; IMMUNOLOGICAL PARAMETERS; LEUCOCYTE ADHESIVE INHIBITION INDEX; LEUKOCYTE; MALE; MONONUCLEAR CELL; NEUROIMMUNOLOGY; NEUROPROTECTION; NISSL SUBSTANCE; NONHUMAN; PHAGOCYTOSIS; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; RAT; TREATMENT RESPONSE; ADULT; HYDROCORTISONE BLOOD LEVEL; LEUKOCYTE ADHERENCE INHIBITION; NERVE DEGENERATION; PROTEIN ANALYSIS; ANIMAL; BLOOD; BODY WEIGHT; BRAIN; CHEMICALLY INDUCED; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; IMMUNOLOGY; LYMPHOCYTE; METABOLISM; PATHOLOGY; PHAGOCYTE; SPLEEN; TIME;

ALZHEIMER DISEASE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BODY WEIGHT; BRAIN; COLCHICINE; CYTOKINES; DISEASE MODELS, ANIMAL; HYDROCORTISONE; LYMPHOCYTES; MALE; NAPROXEN; NITRITES; PHAGOCYTES; PLAQUE, AMYLOID; RATS; REACTIVE OXYGEN SPECIES; SPLEEN; TIME FACTORS; TUBULIN MODULATORS;

EID: 84906940468     PISSN: 10217401     EISSN: 14230216     Source Type: Journal    
DOI: 10.1159/000357735     Document Type: Article

References (67)

1. Berg L, McKeel DW Jr, Miller JP, Baty J, Morris JC: Neuropathological indexes of Alzheimer's disease in demented and nondemented persons aged 80 years and older. Arch Neurol 1993; 50: 349-358.
2. Braak H, Braak E: Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997; 18: 351-357.
3. Braak H, Braak E: Evolution of neuronal changes in the course of Alzheimer's disease. J Neural Transm Suppl 1998; 53: 127-140.
4. Braak H, Braak E, Bohl J, Bratzke H: Evolution of Alzheimer's disease related cortical lesions. J Neural Transm Suppl 1998; 54: 97-106.
5. Huberman M, Shalit F, Roth-Deri I, Gutman B, Brodie C, Ko HE, Sredini B: Correlation of cytokine secretion by mononuclear cells of Alzheimer patients and their disease stage. J Neuroimmunol 1999; 52: 147-152.
6. Jellinger KA, Bancher C: AD neuropathology. Neurology 1996; 46: 1186-1187.
7. Brion JP: Neurofibrillary tangles and Alzheimer's disease. Eur Neurol 1998; 40: 130-140.
8. Blennow K, Leon MJ, Zeterberg H: Alzheimer's disease. Lancet 2006; 368: 387-403.
9. Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-356.
10. Armstrong RA: Plaques and tangles and the pathogenesis of Alzheimer's disease. Folia Neuropathol 2006; 44: 1-11.
11. Swerdlow RH, Khan SM: A 'mitochondrial cascade hypothesis' for sporadic Alzheimer's disease. Med Hypotheses 2004; 63: 8-20.
12. Petrisic MA: Amyloid cascade hypothesis: is it true for sporadic Alzheimer's disease. Periodicum Biologorum UDC 2008; 110: 17-25.
13. Popp J, Schaper K, Kölsch H, Cvetanovska G, Rommel F, Klingmüller D, Dodel R, Wüllner U, Jessen F: CSF cortisol in Alzheimer's disease and mild cognitive impairment. Neurobiol Aging 2009; 30: 498-500.
14. Rai S, Kamat PK, Nath C, Shukla R: A study on neuroinflammation and NMDA receptor function in STZ (ICV) induced memory impaired rats. J Neuroimmunol 2013; 254: 1-9.
15. Blum-Degen D, Müller T, Kuhn W, Gerlach M, Przuntek H, Riederer P: Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett 1995; 202: 17-20.
16. Alvarez A, Cacaelos R, Sanpedro C, García-Fantini M, Aleixandre M: Serum TNF-alpha levels are increased and correlate negatively with free IGF-I in Alzheimer disease. Neurobiol Aging 2007; 28: 533-536.
17. McGeer PL, McGeer E, Rogers J, Sibley J: Anti-inflammatory drugs and Alzheimer disease. Lancet 1990; 335: 1037.
18. Breitner JC, Baker LD, Montine TJ, Meinert CL, Lyketsos CG, Ashe KH, Brandt J, Craft S, Evans DE, Green RC, Ismail MS, Martin BK, Mullan MJ, Sabbagh M, Tariot PN; ADAPT Research Group: Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimers Dement 2011; 7: 402-411.
19. Pasero G, Marson P: A short history of antirheumatic therapy. III. Non steroidal anti-inflammatory drugs (in Italian). Reumatismo 2010; 62: 225-232.
20. Dhull DK, Jindal A, Dhull RK, Aggarwal S, Bhateja D, Padi SSV: Neuroprotective effect of cyclooxygenase inhibitors in ICV-STZ induced sporadic Alzheimer's disease in rats. J Mol Neurosci 2012; 46: 223-235.
21. Morteau O: Prostaglandins and inflammation: the cyclooxygenase controversy. Arch Immunol Ther Exp (Warsz) 2000; 48: 473-480.
22. Yasojima K, Schwab C, McGeer EG, McGeer PL: Distribution of cyclooxygenase-1 and cyclooxygenase- 2 mRNAs and proteins in human brain and peripheral organs. Brain Res 1999; 830: 226-236.
23. Zarghi A, Arfaei S: Selective COX-2 inhibitors: a review of their structure-activity relationships. Iran J Pharm Res 2011; 10: 655-683.
24. Britschgi M, Wyss-Coray T: Systemic and acquired immune responses in Alzheimer's disease. Int Rev Neurobiol 2007; 82: 205-233.
25. Shalit F, Sredni B, Stern L, Kott E, Huberman M: Elevated interleukin-6 secretion levels by mononuclear cells of Alzheimer's patients. Neurosci Lett 1994; 174: 130-132.
26. Soleret SB, Fioravantla M, Pascale AL, Ferrari E, Govoni S, Battaini F: Increased natural killer cell cytotoxicity in Alzheimer's disease may involve protein kinase C dysregulation. Neurobiol Aging 1998; 19: 191-199.
27. Giménez-Llort L, Maté I, Manassra R, Vida C, De La Fuente M: Peripheral immune system and neuroimmune communication impairment in a mouse model of Alzheimer's disease. Ann NY Acad Sci 2012; 1262: 74-84.
28. Kumar A, Seghal N, Naidu PS, Padi SSV, Goyal R: Colchicines-induced neurotoxicity as an animal model of sporadic dementia of Alzheimer's type. Pharmacol Rep 2007; 59: 274-283.
29. Ganguly R, Guha D: Alteration of brain monoamines & EEG wave pattern in rat model of Alzheimer's disease & protection by Moringa oleifera. Indian J Med Res 2008; 128: 744-751.
30. Pitchaimani V, Arumugam S, Thandavarayan RA, Thiyagarajan MK, Aiyalu R, Sreedhar R, Nakamura T, Watanabe JK: Nootropic activity of acetaminophen against colchicine induced cognitive impairment in rats. J Clin Biochem Nutr 2012; 50: 241-244.
31. Paxinos G, Watson CR, Emson PC: AChEstained horizontal sections of the rat brain in stereotaxic coordinates. J Neurosci Methods 1980; 3: 129-149.
32. Csölle C, Sperlágh B: Peripheral origin of IL- 1β production in the rodent hippocampus under in vivo systemic bacterial lipopolysaccharide (LPS) challenge and its regulation by P2X(7) receptors. J Neuroimmunol 2010; 219: 38-46.
33. Csölle C, Sperlágh B: Endocannabinergic modulation of interleukin-1β in mouse hippocampus under basal conditions and after in vivo systemic lipopolysaccharide stimulation. Neuroimmunomodulation 2011; 18: 226-231.
34. Socci DJ, Bjugstad KB, Jones HC, Pattisapu JV, Arendash GW: Evidence that oxidative stress is associated with the pathophysiology of inherited hydrocephalus in the H-Tx rat model. Exp Neurol 1999; 155: 109-117.
35. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR: Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal Biochem 1982; 126: 131-138.
36. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275.
37. Maluish AE, Halliday WJ: Hemocytometer leukocyte adherence technique. Cancer Res 1979; 39: 625-626.
38. Oben JA, Foreman JC: A simple quantitative fluorimetric assay of in vitro phagocytosis in human neutrophils. J Immunol Methods 1998; 112: 99-103.
39. Hudson L, Hay FC: Polymorphonuclear (PMN) assay for neutrophil phagocytic activity; in Hudson L, Hay FC: Practical Immunology. Oxford, Blackwell, 1980, vol 2, pp 29-31.
40. Weidmann E, Brieger J, Jahn B, Hoelzer D, Bergmann L, Mitrou PS: Lactate dehydrogenase-release assay: a reliable, nonradioactive technique for analysis of cytotoxic lymphocyte-mediated lytic activity against blasts from acute myelocytic leukemia. Ann Hematol 1995; 70: 153-158.
41. Dutta G, Mondal N, Goswami A, Majumdar D, Ghosh T: Effects of electrolytic lesion of medial septum on some immune responses in rats. Neuroimmunomodulation 2011; 18: 232-239.
42. Cox G: Neuropathological techniques; in Bancroft JD, Stevens A (eds): Theory and Practice of Histological Techniques. New York, Churchill Livingstone, 1977, vol 1, pp 258-259.
43. Stevens A, Bancroft JD: Proteins and nucleic acids; in Bancroft JD, Stevens A (eds): Theory and Practice of Histological Techniques. New York, Churchill Livingstone, 1977, vol 1, pp 129.
44. Nakayama T, Sawada T: Involvement of microtubule integrity in memory impairment caused by colchicines. Pharmacol Biochem Behav 2002; 71: 119-138.
45. Frijlink HW, Franssen EJ, Eissens AC, Oosting R, Lerk CF, Meijer DK, Golby A, Silverberg G, Race E, Gabrieli S, O'Shea J, Knierim K, Stebbins G, Gabrieli J: Memory encoding in Alzheimer's disease: an fMRI study of explicit and implicit memory. Brain 2005; 128: 773-787.
46. Kim S, Chang E, Kumar R, Klimov DK: Naproxen interferes with the assembly of Aβ oligomers implicated in Alzheimer's disease. Biophys J 2011; 100: 2024-2032.
47. Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen P, Kayed R, Glabe CG, Frautschy SA, Cole GM: Curcumin inhibits formation of amyloid β oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 2005; 280: 5892-5901.
48. Naxen, Naproxen. http://www.medsafe.govt. nz/profs/datasheet/n/naxentab. pdf (accessed July 6, 2013).
49. Kumar A, Seghal N, Padi SV, Naidu PS: Differential effects of cyclooxygenase inhibitors on intracerebroventricular colchicine-induced dysfunction and oxidative stress in rats. Eur J Pharmacol 2006; 551: 58-66.
50. Gehrmann J, Matsumoto Y, Kreutzberg GW: Microglia: intrinsic immuneffector cell of the brain. Brain Res Brain Res Rev 1995; 20: 269-287.
51. Wilson L: Microtubules as targets for drug and toxic chemical action: the mechanisms of colchicine and vinblastine; in Clarkson TW, Sagar PR, Syversen TLM (eds): The Cytoskeleton - A Target for Toxic Agents. New York, Plenum, 1986, pp 37-52.
52. Emerich DF, Walsh TJ: Cholinergic cell loss and cognitive impairments following intraventricular or intradentate colchicines. Brain Res 1990; 517: 157-167.
53. Koo EH, Sisodia SS, Archer DR, Martin U, Weideman A, Beyreuther K, Fischer P, Masters CL, Price DL: Precursor of amyloid protein in Alzheimer disease undergoes fast anterograde axonal transport. Proc Natl Acad Sci USA 1990; 87: 1561-1565.
54. Koo EH, Sisodia SS, Archer DR, Martin U, Weideman A, Beyreuther K, Fischer P, Masters CL, Price DL: Precursor of amyloid protein in Alzheimer disease undergoes fast anterograde axonal transport. Proc Natl Acad Sci USA 1990; 87: 1561-1565.
55. Wisniewski H, Terry RD: Experimental colchicine encephalopathy. I. Induction of neurofibrillary degeneration. Lab Invest 1967; 17: 577-587.
56. Klatzo I, Wisniewski H, Streicher E: Experimental production of neurofibrillary degeneration. I. Light microscopic observations. J Neuropathol Exp Neurol 1965; 24: 187-199.
57. Hirsch EC, Hunot S: Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 2009; 8: 382-97.
58. Aloisi F: Immune Function of Microglia. Glia 2001; 36: 165-179.
59. Nyoman G, Darmadipura S: The role of microglia as prime component of CNS immune system in acute and chronic neuroinflammation. Folia Med Indones 2007; 43: 54-58.
60. Mallat M, Chamak B: Brain macrophages: neurotoxic or neurotrophic effector cells? J Leukoc Biol 1994; 56: 416-422.
61. Minton K: Immune mechanisms in neurological disorders: protective or destructive? Trends Immunol 2001; 22: 655-657.
62. Streit WJ: Microglia as neuroprotective, immunocompetent cells of the CNS. Glia 2002; 40: 133-139.
63. Streit WJ: Microglial-neuronal interactions. J Chem Neuroanat 1993; 6: 261-266.
64. Ji L, Li LP, Schnitzer T, Du H, Prasad PV: Intra-renal oxygenation in rat kidneys during water loading: effects of cyclooxygenase (COX) inhibition and nitric oxide (NO) donation. J Magn Reson Imaging 2010; 32: 383-387.
65. Amer M, Bead VR, Bathon J, Blumenthal RS, Edwards DN: Use of nonsteroidal anti-inflammatory drugs in patients with cardiovascular disease: a cautionary tale. Cardiol Rev 2010; 18: 204-212.
66. Goulding NJ, Flower RJ: Glucocorticoids and the immune system; in Buckingham JC, Gillies GE, Cowell A (eds): Stress, Stress Hormone and the Immune System. New York, Wiley, 1993, pp 199-223.
67. Swabb DF, Raadsheer FC, Endert E, Hoffman MA, Kamphorst W, Ravid R: Increased cortisol levels in aging and Alzheimer's disease in postmortem cerebrospinal fluid. J Neuroendocrinol 1994; 6: 681-687.